查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
2022-2029 年免疫檢查點抑製劑的全球市場
市場調查報告書
商品編碼
1153824

2022-2029 年免疫檢查點抑製劑的全球市場

Global Immune Checkpoint Inhibitors Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 200 Pages | 商品交期: 約2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場概覽

全球免疫檢查點抑製劑市場預計在2021年達到311.5029億美元，2029年達到1324.2741億美元，預測期內（2022-2029年）的複合年增長率為14.58%。

免疫檢查點抑製劑是由抗體製成的藥物，可釋放免疫系統對癌細胞的攻擊。檢查點抑製劑旨在克服癌症對免疫系統攻擊的主要防御之一。檢查點抑製劑阻斷癌細胞中的正常蛋白質和 T 細胞中的蛋白質。結果，阻止 T 細胞識別癌細胞的眼罩被移除，導致免疫系統攻擊癌細胞。

市場動態

對這些免疫檢查點抑製劑的需求不斷增長、臨床試驗的良好結果、研發支出的增加以及新產品推出的增加預計將推動市場增長。

新產品的推出和對免疫檢查點抑製劑設備的需求增加將推動市場增長。

全球免疫檢查點抑製劑市場的推動因素包括：醫療保健行業對免疫檢查點抑製劑的需求激增、產品發布不斷增加、臨床試驗取得良好結果以及患者數量比單獨使用傳統化療更多。優勢在於主要因素。各種處於臨床階段的藥物在治療各種癌症方面都顯示出了良好的效果。例如，2021 年 10 月，阿斯利康的 HIMALAYA III 期試驗報告了高水平的有利結果。對於未接受全身治療的無法切除的肝細胞癌患者，與索拉非尼相比，單劑量 tremelimumab 聯合 Imfinzi 可顯著改善總生存期。這種新的給藥方案被稱為 STRIDE 方案。

隨著各種最先進的技術進步，免疫檢查點抑製劑藥物正在興起，需求也在增加。例如，2022年6月，羅氏宣布Tecentriq（atezolizumab）獲歐盟委員會批准用於治療非小細胞肺癌。 Tecentriq 是針對 PD-L1 >50% 且複發風險高的非小細胞肺癌患者進行完全切除和鉑類化療後的輔助治療。

與免疫檢查點抑製劑治療相關的高成本阻礙了市場增長。

與檢查點抑製劑相關的高昂治療費用將抑制市場增長。根據 2021 年 12 月發表的《臨床路徑雜誌》報告“在一線非小細胞肺癌中延長使用免疫檢查點抑製劑的成本”，免疫檢查點抑製劑的平均成本約為 148,431 美元。美元（約1000 萬日元）。 nivolumab/ipilimumab 的成本約為 544,696 美元。

COVID-19 影響分析

疫情對全球金融預期、運營和危機應對策略產生了負面影響。市場進入者正在通過利用研究市場和創造尖端項目來對抗這種流行病，從而改變他們的長期和短期增長戰略。即使 COVID-19 損害了行業，重要的是要為您的業務運營製定並儘快制定備份計劃。世界各地正在進行各種合作和合併，推動了市場的增長。例如，2022 年 1 月，阿斯利康 (AstraZeneca) 將與 Scorpion Therapeutics 合作，研究、開發和商業化針對難以靶向的癌症蛋白的精準藥物，這可能會改變癌症治療。

內容

第 1 章市場研究方法和範圍

  • 調查方法
  • 調查目的和範圍

第 2 章市場定義和概述

第 3 章執行摘要

第四章市場動態

  • 市場影響因素
    • 司機
      • 新產品發布次數增加
      • 對免疫檢查點抑製劑的需求不斷增長
    • 約束因素
      • 與抑製劑相關的高成本
    • 商機
    • 影響分析

第五章行業分析

  • 搬運工的五種力量
  • 未滿足的需求
  • 供應鏈分析
  • 監管分析

第 6 章 COVID-19 分析

  • COVID-19 市場分析
    • COVID-19 之前的市場情景
    • COVID-19 的當前市場情景
    • COVID-19 後或未來情景
  • COVID-19 期間的價格動態
  • 供需範圍
  • 大流行期間與市場相關的政府舉措
  • 製造商的戰略舉措
  • 總結

第 7 章藥物類別

  • 程序性死亡受體 1 抑製劑 (PD-1)
    • 派姆單抗
    • Cemiplimab
    • 納武單抗
    • 其他
  • 程序性死亡配體 1 抑製劑 (PDL-1)
    • Avelumab
    • 阿特珠單抗
    • 度伐單抗
  • 細胞毒性 T 淋巴細胞抗原 4 抑製劑 (CTLA-4)
    • 易普利姆瑪
  • 淋巴細胞活化基因 3 抑製劑 (LAG-3)
    • Leratolimab

第八章應用

  • 肺癌
  • 血癌
  • 膀胱癌
  • 霍奇金淋巴瘤
  • 黑色素瘤
  • 乳腺癌
  • 宮頸癌
  • 其他

第 9 章分銷渠道

  • 醫院藥房
  • 零售藥房
  • 在線藥店

第10章按地區

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 意大利
    • 西班牙
    • 其他歐洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 其他亞太地區
  • 中東和非洲

第11章競爭格局

  • 主要發展和戰略
  • 公司股票分析
  • 產品基準
  • 值得關注的主要公司名單

第12章公司簡介

  • AstraZeneca PLC
    • 公司簡介
    • 產品組合和說明
    • 主要亮點
    • 財務摘要
  • Bristol-Myers Squibb
  • Roche Holdings AG
  • Novartis AG
  • Pfizer Inc.
  • Sanofi
  • Merck & Co., Inc
  • Ono Pharmaceutical Co.
  • Kite Pharma, Inc（Gilead company）
  • F. Hoffmann-La Roche AG

第13章 免疫檢查點抑製劑的全球市場-DataM

簡介目錄
Product Code: DMPH867

Market Overview

The global immune checkpoint inhibitors market was valued at US$ 31,150.29 million in 2021 and is estimated to reach US$ 132,427.41 million by 2029, growing at a CAGR of 14.58% during the forecast period (2022-2029).

The immune checkpoint inhibitor is a drug made of antibodies that unleashes an immune system attack on cancer cells. Checkpoint inhibitors seek to overcome one of cancer's primary defenses against an immune system attack. Checkpoint inhibitors block normal proteins in cancer cells or the proteins in T cells. The result is removing the blinders that prevented T cells from recognizing them as cancerous, leading to an immune system assault on them.

Market Dynamics

The increasing demand for these immune checkpoint inhibitors, positive results in clinical trials, the increasing research and development expenditure and growth in novel product launches are expected to drive market growth.

The increasing novel product launches and demand for immune checkpoint inhibitor devices drive market growth.

The global market for immune checkpoint inhibitors is primarily driven by the surge in demand for immune checkpoint inhibitor drugs in the healthcare industry, the rising number of product launches, positive results from clinical trials, and the many advantages over traditional chemotherapy alone. Various drugs in the clinical stage are showing good results in the treatment of various cancers. For instance, in Oct 2021, AstraZeneca' HIMALAYA phase III trial reported positive high-level results. The single dose of tremelimumab and Imfinzi showed a clinically significant overall survival benefit compared with sorafenib for 1st line treatment for unresectable hepatocellular carcinoma patients who haven't gotten systemic therapy. This new dose is known as the STRIDE regimen.

Various latest technological advancements are taking place, and the number of immune checkpoint inhibitors drug launches is increasing, increasing the demand as well. For instance, in Jun 2022, Roche announced the approval of Tecentriq (atezolizumab) for treating non-small cell lung cancer by the European Commission. Tecentriq is an adjuvant treatment that follows full resection and chemotherapy (platinum-based) for non-small cell lung cancer patients with high recurrence risk with PD-L1>50% tumor expression.

High costs associated with immune checkpoint inhibitors therapy will hamper the market's growth.

The high cost of therapies related to checkpoint inhibitors will restrain the market growth. According to the Journal of Clinical Pathways report published in Dec 2021, titled "Cost of extended use of immune checkpoint inhibitors in first-line non-small cell lung cancer," the average cost of immune checkpoint inhibitors is around $148,431. Cost of nivolumab/ipilimumab were around $544,696.

COVID-19 Impact Analysis

The pandemic has negatively impacted global financial expectations, operations and crisis response strategy. Market participants are changing their long-term and short-term growth strategies by utilizing the research market and creating cutting-edge items to combat the pandemic. Even though COVID-19 harms the industry, preparing and implementing backup plans as soon as possible for business operations is crucial. Various collaborations and mergers are happening worldwide, boosting the market's growth. For instance, in Jan 2022, AstraZeneca collaborated with Scorpion Therapeutics to research, develop and market precision medicines against the hard-to-target cancer proteins, potentially transforming the oncology treatment.

Segment Analysis

The programmed death receptor 1 inhibitor (PD-1) drug segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)

The programmed death receptor 1 inhibitor (PD-1) segment is the highest market holder in the global immune checkpoint inhibitors market. The programmed death receptor 1 inhibitor (PD-1) share accounted for the largest market because of its novel, innovative drug launches, an increasing number of pipelines and increasing prevalence of cancer. PD-1 is a checkpoint protein on the T cells (immune cells), which plays the role of an "off switch" that prevents T cells from attacking the body's other cells. It controls it at the time of its attachment with PD-L1, a kind of protein on a few normal and cancerous cells. When the binding occurs, the T-cell gets the message not to kill the cell. Few cancerous cells have a huge amount of PD-L1, which helps them to hide from immune attacks easily. The monoclonal antibodies targeting PD-1 inhibit the binding of PD-1 with PD-L1, ultimately increasing the immune response against cancerous cells. According to the WHO report 2022, cancer caused approximately ten million deaths globally, making it the major cause globally in 2020. The most common reason for cancer death was lung cancer accounting for around 1.80 million deaths. The novel development of these PD-1 inhibitors will benefit various cancer treatments. Increasing regulatory approvals of these PD-1 inhibitors are increasing market growth. For instance, in Aug 2021, GlaxoSmith Kline announced the approval of Jemparli (dostarlimab), a PD-1 immune checkpoint inhibitor for patients with advanced endometrial cancer and mismatch repair deficient recurrence.

Geographical Analysis

North America holds the largest market share of the global immune checkpoint inhibitors market.

North America dominates the global immune checkpoint inhibitors market, primarily attributed to the increasing number of partnerships or collaborations between companies, the rising demand for immune checkpoint inhibitor drugs, and novel studies. Furthermore, factors including growing expenditure on research and development and the increasing incidence of cancer will likely enhance the growth of the region's immune checkpoint inhibitors market.

Moreover, the growing number of product launches is responsible for the market's growth. Other factors, such as the high spending of GDP on healthcare, stimulate the market's growth. Many key developments are taking place based in this region. For instance, in Sep 2022, AstraZeneca announced the approval of Imfinzi (durvalumab) by the United States Food and Drug Administration for treating metastatic or locally advanced biliary tract cancer patients with chemotherapy. This approval was based on a phase III trial of TOPAZ-1, where Imfinzi and chemotherapy minimized the death risk by 20% compared to chemotherapy alone.

Competitive Landscape

The immune checkpoint inhibitors market is highly competitive with local and global companies. AstraZeneca, Bristol-Myers Squibb, Roche Holdings AG, Novartis AG, Pfizer Inc., Sanofi, Merck & Co., Inc, Key players contributing to the market's growth Ono Pharmaceutical Co., Kite Pharma, Inc (Gilead company), F. Hoffmann-La Roche AG and more. The key players are adopting various growth strategies such as product launches, mergers & acquisitions, partnerships, and collaborations, contributing to the market's growth. For instance, in Apr 2020, Kite, Gilead Company and oNKo-innate announced their collaboration for research in cancer immunotherapy. Both companies entered in 2-year collaboration to support the development of next-gen drug therapies and engineered cell therapies focusing on natural killer cells (NK).

AstraZeneca PLC:

Overview:

AstraZeneca is a science-led, bio-pharmaceutical company that researches, develops and markets prescription medicines. It was established in 1999 and is headquartered in Cambridge, United Kingdom.

Product Portfolio:

Imfinzi (Durvalumab): This is an immune checkpoint inhibitor, a human immunoglobulin G1 monoclonal antibody used as immunotherapy for certain cancers. It inhibits the interaction between programmed cell death ligand 1 with programmed death receptor 1.

Key Development: In Aug 2022, AstraZeneca announced that it had completely acquired TeneoTwo Inc. This acquisition includes TeneoTwo's TNB-486, evaluated in B-cell non-Hodgkin lymphoma, phase I clinical stage CD19/CD3 T-cell engager.

The global immune checkpoint inhibitors market report would provide access to approximately 40+ market data tables, 45+ figures, and 200 (approximate) pages.

Table of Contents

1. Market Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. The rising novel product launches
      • 4.1.1.2. Increasing demand for immune checkpoint inhibitor drugs
    • 4.1.2. Restraints:
      • 4.1.2.1. High cost associated with these inhibitors
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces
  • 5.2. Unmet Needs
  • 5.3. Supply chain Analysis
  • 5.4. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturer's Strategic Initiatives
  • 6.6. Conclusion

7. By Drug Class

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 7.1.2. Market Attractiveness Index, By Drug Class
  • 7.2. Programmed Death Receptor 1 Inhibitor (PD-1) *
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
    • 7.2.3. Pembrolizumab
    • 7.2.4. Cemiplimab
    • 7.2.5. Nivolumab
    • 7.2.6. Others
  • 7.3. Programmed Death Ligand 1 Inhibitors (PDL-1)
    • 7.3.1. Avelumab
    • 7.3.2. Atezolizumab
    • 7.3.3. Durvalumab
  • 7.4. Cytotoxic T Lymphocyte Antigen 4 Inhibitors (CTLA-4)
    • 7.4.1. Ipilimumab
  • 7.5. Lymphocyte Activation Gene 3 Inhibitors (LAG-3)
    • 7.5.1. Relatlimab

8. By Application

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.1.2. Market Attractiveness Index, By Application
  • 8.2. Lung Cancer *
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Blood Cancer
  • 8.4. Bladder Cancer
  • 8.5. Hodgkin Lymphoma
  • 8.6. Melanoma
  • 8.7. Breast Cancer
  • 8.8. Cervical Cancer
  • 8.9. Others

9. By Distribution Channel

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Distribution Channel
    • 9.1.2. Market Attractiveness Index, By Distribution Channel
  • 9.2. Hospital Pharmacies *
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Retail Pharmacies
  • 9.4. Online Pharmacies

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), Distribution Channel
    • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. The U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), Distribution Channel
    • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. The U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), Distribution Channel
    • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), Distribution Channel
    • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), Distribution Channel
    • 10.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

11. Competitive Landscape

  • 11.1. Key Developments and Strategies
  • 11.2. Company Share Analysis
  • 11.3. Product Benchmarking
  • 11.4. List of Key Companies to Watch

12. Company Profiles

  • 12.1. AstraZeneca PLC
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. Bristol-Myers Squibb
  • 12.3. Roche Holdings AG
  • 12.4. Novartis AG
  • 12.5. Pfizer Inc.
  • 12.6. Sanofi
  • 12.7. Merck & Co., Inc
  • 12.8. Ono Pharmaceutical Co.
  • 12.9. Kite Pharma, Inc (Gilead company)
  • 12.10. F. Hoffmann-La Roche AG

LIST NOT EXHAUSTIVE

13. Global Immune Checkpoint Inhibitors Market- DataM

  • 13.1. Appendix
  • 13.2. About Us and Services
  • 13.3. Contact Us